Management of endometrial cancer in Asia: consensus statement from the Asian Oncology Summit 2009.
Endometrial cancer is one of the gynaecological cancers that carries good overall prognosis because it is often detected at early stages of disease. The International Federation of Gynecology and Obstetrics replaced clinical staging with surgical staging in 1988 and updated the system in 2009. Controversies remain regarding the recommended screening protocol for women with a high risk of endometrial cancer, the role and benefit of retroperitoneal lymph-node dissection, the necessity of ovarian resection, the benefit and type of adjuvant radiation therapy, and the safety of hormone-replacement therapy after treatment. This article reviews the available evidence for optimum management of endometrial cancer and how management strategies can be applied in Asian countries with different levels of health-care resource availability and economic development. An overview of the literature for endometrial-cancer screening, diagnosis, and management is discussed. Consensus statements are formulated on the basis of basic, limited, enhanced, and maximum health-care resource availability, using the framework provided by the Breast Health Global Initiative.
Tangjitgamol
Siriwan
S
Department of Obstetrics and Gynecology, Bangkok Metropolitan Administration Medical College and Vajira Hospital, Bangkok, Thailand.
Anderson
Benjamin O
BO
See
Hui Ti
HT
Lertbutsayanukul
Chawalit
C
Sirisabya
Nakarin
N
Manchana
Tarinee
T
Ilancheran
Arunachalam
A
Lee
Khai Mun
KM
Lim
Siew Eng
SE
Chia
Yin-Nin
YN
Domingo
Efren
E
Kim
Young-Tak
YT
Lai
Chyong-Huey
CH
Dali
Ahmad Zailani Hatta Mohd
AZ
Supakapongkul
Wisit
W
Wilailak
Sarikapan
S
Tay
Eng-Hseon
EH
Kavanagh
John
J
D001208:Asia / Q000453:epidemiology; D017024:Chemotherapy, Adjuvant; D003226:Congresses as Topic; D003362:Cost-Benefit Analysis; D003906:Developing Countries / Q000191:economics; D016527:Drug Costs; D042241:Early Diagnosis; D016889:Endometrial Neoplasms / Q000175:diagnosis / Q000191:economics / Q000401:mortality / Q000628:therapy*; D019317:Evidence-Based Medicine; D005260:Female; D019983:Guideline Adherence; D013509:Gynecologic Surgical Procedures / Q000191:economics; D017048:Health Care Costs; D006297:Health Services Accessibility; D054625:Healthcare Disparities; D020249:Hormone Replacement Therapy / Q000009:adverse effects / Q000191:economics; D006801:Humans; D008197:Lymph Node Excision; D008403:Mass Screening; D008495:Medical Oncology / Q000191:economics / Q000592:standards; D009367:Neoplasm Staging; D011237:Predictive Value of Tests; D018714:Radiotherapy, Adjuvant; D018570:Risk Assessment; D016896:Treatment Outcome